Human Genome Sciences Buys Principia Pharmaceutical for $120 Million | GenomeWeb

NEW YORK, Sept. 11 – In a move that brings it a step closer to its goal of becoming a global pharmaceutical company, gene-based drug discovery company Human Genome Sciences (Nasdaq: HGSI) said Monday it had acquired privately held Principia Pharmaceutical for about $120 million in stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.